financetom
Business
financetom
/
Business
/
Proxy advisor Glass Lewis advises Enhabit investors to elect three AREX nominees
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Proxy advisor Glass Lewis advises Enhabit investors to elect three AREX nominees
Jul 18, 2024 6:13 AM

(Reuters) - Proxy advisory firm Glass Lewis said on Thursday Enhabit shareholders should elect three AREX Capital Management director candidates to the nine-member board.

It advised choosing AREX nominees Maxine Hochhauser, Mark Ohlendorf and Gregory Sheff, according to its report seen by Reuters.

"There is a valid case to be made for supporting at least incremental change to the company's board, given the company's financial underperformance relative to its closest peers, the company's missteps in the strategic review process and the relevant experience and expertise of the dissident nominees," the report said.

The recommendation comes days after Glass Lewis' bigger rival Institutional Shareholder Services (ISS) said shareholders should elect three AREX director candidates.

Together ISS and Glass Lewis often influence how investors vote on proposed mergers and who serves on a company's board.

Shareholders will vote on July 25 unless the two sides reach an agreement beforehand.

AREX has been asking investors to replace seven directors to help reverse poor financial performance at the two-year-old company.

It has also been pushing the home health and hospice provider to put itself up for sale as its stock price has dropped 61% since it became a standalone company. In the last five days, the stock price has climbed nearly 10%.

The company, which is urging shareholders to elect all nine of its directors, decided earlier this year to remain an independent company.

It earlier this week said second-quarter profit could be in the range of $24.5 to $25.0 million when it reports results next month.

It reported adjusted earnings before interest, taxes, depreciation and amortization of $25.3 million in the first quarter.

AREX, which owns a 4.9% stake in Enhabit ( EHAB ), is backing CEO Barbara Jacobsmeyer and director Barry Schochet for re-election.

Schochet joined the board last year when the company reached an agreement with investors Cruiser Capital and Harbour Point Capital Management in March 2023.

(Reporting by Svea Herbst-Bayliss; Editing by Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved